About journal  
             Home | Brief Introduction | Editorial Board | Notice to Contributors | Editorial Policy | Subscription | Advertisement | Download | Guestbook | 中文版  
 
沈亚,高连娣,程金伟,蔡季平,李由,魏锐利.非穿透性小梁手术联合应用丝裂霉素C治疗开角型青光眼的meta分析[J].Academic Journal of Second Military Medical University ,2012,33(9):1006-1011
非穿透性小梁手术联合应用丝裂霉素C治疗开角型青光眼的meta分析    点此下载全文 Fulltext
沈亚  高连娣  程金伟  蔡季平  李由  魏锐利*
第二军医大学长征医院眼科,上海 200003
共同第一作者
*通信作者
基金项目:国家自然科学基金(81000374,81170874),上海市自然科学基金(10ZR1439300),上海市青年科技启明星计划(12QA1404600).
DOI:10.3724/SP.J.1008.2012.001006
Hits: 496
Download times: 513
摘要:
      目的评价非穿透性小梁手术联合使用丝裂霉素C对治疗开角型青光眼患者的疗效及耐受性的差异。方法检索MEDLINE、EMBASE、中国生物医学文献数据库、Cochrane图书馆,获得以往发表的相关论文,经筛选后共有8项临床对照试验纳入meta分析。比较非穿透性小梁手术联合使用与未使用丝裂霉素C的眼压下降百分比、治疗完全成功率、治疗总成功率和并发症等指标。使用RevMan 5.0软件进行统计分析。结果术后6、12、24、36个月非穿透性小梁手术联合使用丝裂霉素C组与单纯非穿透性小梁手术组眼压下降百分比的加权均数差分别为5.24%(95%CI,-3.24~13.72)、8.31%(95%CI,4.33~12.30)、9.56%(95%CI,4.88~14.24)、14.45%(95%CI,9.02~19.88),除术后6个月外的其余各个时间点两组之间差异均存在统计学意义(P<0.05)。非穿透性小梁手术联合使用丝裂霉素C组的治疗完全成功率较单纯非穿透性小梁手术组增加,治疗完全成功率的合并风险差在术后6、12、24、36个月分别为1.16(95%CI,1.05~1.27)、1.20(95%CI,1.05~1.38)、1.30(95%CI,1.05~1.61)、1.36(95%CI,1.06~1.73),各个时间点两组之间差异均存在统计学意义(P<0.05)。术中应用丝裂霉素C未出现与药物相关的并发症。结论联合应用丝裂霉素C可以改善非穿透性小梁手术的疗效,而且耐受性良好。
关键词:开角型青光眼  非穿透性小梁手术  丝裂霉素C  meta分析
Intra-operative mitomycin C for nonpenetrating filtering surgery in treatment of open angle glaucoma: a systematic review and meta-analysis    Fulltext
SHEN Ya  GAO Lian-di  CHENG Jin-wei  CAI Ji-ping  LI You  WEI Rui-li*
Department of Ophthalmology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China
Co-first authors.
*Corresponding author.
Fund Project:Supported by National Natural Science Foundation of China(81000374,81170874), Natural Science Foundation of Shanghai(10ZR1439300), and Shanghai Rising-Star Program for Young Scientists (12QA1404600).
Abstract:
      ObjectiveTo compare the efficacy and tolerability between nonpenetrating filtering surgery with (NPFS-MMC) and without (NPFS-noMMC) intraoperative mitomycin C application for treatment open angle glaucoma. MethodsPertinent studies were selected through extensive searches of the Cochrane Library, PubMed, Embase, and Chinese Biomedicine Database. Eight controlled clinical trials meeting the pre-defined criteria were systematically reviewed by meta-analysis. The main outcome measures were percentage intraocular pressure reduction (IOPR%), complete remission rate, total remission rate, and complications. The pooled estimates were carried out using RevMan version 5.0 software. ResultsThe weighted mean differences of the IOPR% between the NPFS-MMC group and NPFS-noMMC group were 5.24% (95% confidence intervals\[95%CI\], -3.24 to 13.72) after 6 months, 8.31% (95%CI,4.33 to 12.30) after 12 months(P<0.05), 9.56% (95%CI, 4.88 to 14.24) after 24 months(P<0.05), and 14.45% (95%CI, 9.02 to 19.88) after 36 months(P<0.05). NPFS-MMC was associated with significant greater complete remission rates compared with NPFS-noMMC, with the pooled risk difference being 1.16 (95%CI, 1.05 to 1.27) after 6 months(P<0.05), 1.20 (95%CI, 1.05 to 1.38) after 12 months (P<0.05), 1.30 (95%CI, 1.05 to 1.61) after 24 months (P<0.05), and 1.36 (95%CI, 1.06 to 1.73) after 36 months (P<0.05). Intraoperative mitomycin C was not associated with any drug-induced complications. ConclusionThe use of intraoperative mitomycin C is safe and can improve the effect of nonpenetrating filtering surgery in patients with open ganle glaucoma.
Keywords:open-angle glaucoma  nonpenetrating filtering surgery  mitomycin C  meta-analysis
View Full Text  View/Add Comment  Download reader

You are guest number 1205646    沪ICP备10039470号-2
Sponsored by:第二军医大学 Publish by:
Address:上海市翔殷路800号 Postcode:200433 Tel:021-25074344 Fax:021-25074344 E-mail:bxue@smmu.edu.cn
Beijing E-tiller Co.,Ltd.